Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | ACACA | Q13085 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513715 | 0.89 | ALDH1A1 (0.50) | HSD17B10TSHRALDH1A1GAASMN1; SMN2 | |
| SCHEMBL6235404 | 0.89 | SMN1; SMN2 (0.52) | HSD17B10ALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL7018700 | 0.85 | SMN1; SMN2 (0.46) | HSD17B10ALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL6237223 | 0.85 | TSHR (0.42) | HSD17B10TSHRALDH1A1GAASMN1; SMN2 | |
| SCHEMBL27202783 | 0.84 | HSD17B10 (0.46) | HSD17B10TSHRALDH1A1GAASMN1; SMN2 | |
| SCHEMBL7025417 | 0.84 | ADORA2B (0.40) | HSD17B10TSHRALDH1A1GAASMN1; SMN2 | |
| SCHEMBL7021004 | 0.83 | L3MBTL1 (0.46) | HSD17B10ALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL6236551 | 0.82 | ADORA2B (0.39) | HSD17B10ALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL7033820 | 0.82 | ALDH1A1 (0.44) | HSD17B10TSHRALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2774966 | 0.81 | ADORA2B (0.58) | HSD17B10ALDH1A1GAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055313-B1 | CYCLIC THIENOURACIL CARBOXAMIDE AND ITS USE | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-3055313-B1 | CYCLIC THIENOURACIL CARBOXAMIDE AND ITS USE | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | US | disclosed |
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | US | disclosed |
| EP-3055313-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015052065-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052065-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | HSD17B10 3888/4885TSHR 1305/4885ALDH1A1 1328/4885 |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | HSD17B10 3888/4885TSHR 1305/4885ALDH1A1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.